"5 Explosive Growth Stocks Set to Soar in 2022"
TL;DR
Wall Street analysts are optimistic about the potential for Ginkgo Bioworks and Intellia Therapeutics, with consensus price targets suggesting significant gains of 144% and 202% respectively over the next 12 months. Ginkgo Bioworks, a synthetic biology company, has faced financial challenges despite its innovative work, while Intellia Therapeutics is developing CRISPR-based gene therapies with promising clinical trial data but faces a long road to commercialization.
Topics:businessfinance#crispr-based-gene-therapies#finance#ginkgo-bioworks#growth-stocks#intellia-therapeutics#wall-street
- 2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street The Motley Fool
- 7 Growth Powerhouse Stocks Poised to Surge InvestorPlace
- 5 Top Growth Stocks to Buy as Recession Fears Subside Yahoo Finance
- 3 Top Growth Stocks to Buy Hand Over Fist in February The Motley Fool
- 3 'Strong Buy'-Rated Growth Stocks to Scoop Up Now Barchart
Want the full story? Read the original reporting
Read on The Motley Fool